{"product_id":"new-tools-for-detecting-prostate-cancer-early-a-patients-guide-to-emerging-screening-technologies","title":"New Tools for Detecting Prostate Cancer Early: A Patient's Guide to Emerging Screening Technologies","description":"\u003cp\u003eProstate cancer is the second most common cancer in men worldwide. Today's screening relies mainly on a blood test called prostate-specific antigen (PSA). This test often flags slow-growing tumours that would never cause harm. A new review of the evidence finds that MRI imaging can find dangerous cancers while cutting unnecessary biopsies. This includes faster, cheaper versions such as biparametric MRI. Blood tests, urine tests and saliva-based genetic risk scores can help doctors decide who needs imaging or a biopsy in the first place. Large randomised trials are still urgently needed before these tools can replace or supplement PSA for population-wide screening.\u003c\/p\u003e\n\n\u003ch1\u003eEmerging tools for the early detection of prostate cancer\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why Finding Prostate Cancer Early Is Complicated\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow This Review Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#psa-problem\"\u003eThe Problem With PSA Testing\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#mri\"\u003eMRI Imaging: The Current Gold Standard\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#bpmri\"\u003eBiparametric MRI: A Faster, Contrast-Free Alternative\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ultrashort\"\u003eUltra-Short MRI Protocols\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#mri-screening\"\u003eMRI for Population-Wide Screening\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ultrasound\"\u003eUltrasound-Based Approaches\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#blood-tests\"\u003eBlood-Based Biomarker Tests\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#urine-tests\"\u003eUrine-Based Biomarker Tests\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#prs\"\u003eSaliva-Based Genetic Risk Scores\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of the Evidence\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003ePractical Recommendations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003ePSA is organ-specific but not cancer-specific; only about one in three men with an elevated PSA actually has cancer found on initial assessment.\u003c\/li\u003e\n\u003cli\u003eIn the PRECISION trial, adding MRI before biopsy increased detection of clinically significant cancer by 12% and reduced biopsies by 28%.\u003c\/li\u003e\n\u003cli\u003eIn the PRIME trial of 490 men, biparametric MRI detected clinically significant cancer in 28.8% versus 29.2% for multiparametric MRI, with similar biopsy rates.\u003c\/li\u003e\n\u003cli\u003eFor low-risk Gleason 6 disease (PSA under 10 ng\/mL, stage T2a or lower), the risk of dying from prostate cancer over 10 to 15 years without treatment is less than 3%.\u003c\/li\u003e\n\u003cli\u003eIn the ReIMAGINE trial, 60% of men with clinically significant cancer had a PSA below 3 ng\/mL, so PSA alone would have missed them.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why Finding Prostate Cancer Early Is Complicated\u003c\/h2\u003e\n\n\u003cp\u003eProstate cancer (PCa) is the second most common cancer in men globally. In 2020, roughly \u003cstrong\u003e1.4 million men\u003c\/strong\u003e were diagnosed with prostate cancer worldwide, and that number is projected to reach \u003cstrong\u003e2.9 million by 2040\u003c\/strong\u003e — driven by longer life expectancy and population growth. Prostate cancer is the \u003cstrong\u003efifth leading cause of cancer-related death\u003c\/strong\u003e globally, and most of those deaths come from late diagnosis. When the disease is caught at an early stage, cure rates with radical treatment (surgery or radiation) are excellent.\u003c\/p\u003e\n\n\u003cp\u003eThe challenge is that early detection is not straightforward. The main screening tool is the prostate-specific antigen test (PSA). PSA is a protein made by the prostate gland that leaks into the blood when the prostate is enlarged or diseased. The PSA test is organ-specific but not cancer-specific. That means it can be elevated for reasons other than cancer, including benign prostatic hyperplasia (BPH, an enlarged but non-cancerous prostate) and prostatitis (inflammation of the prostate).\u003c\/p\u003e\n\n\u003cp\u003eThe consequence is a large number of false alarms. \u003cstrong\u003eOnly about one in three men with an elevated PSA will actually have cancer\u003c\/strong\u003e found on initial assessment. And among those who do turn out to have cancer, the majority — \u003cstrong\u003e69.4%\u003c\/strong\u003e — are diagnosed with localised disease, of which roughly half are clinically insignificant (Gleason score ≤6).\u003c\/p\u003e\n\n\u003cp\u003eThe Gleason score is a grading system that describes how abnormal the cancer cells look under a microscope. A score of 6 or below marks a low-grade tumour that grows very slowly. For men with Gleason ≤6 tumours classified as low risk (PSA under 10 ng\/mL and stage ≤T2a), the risk of dying from prostate cancer over 10 to 15 years — even without any treatment — is \u003cstrong\u003eless than 3%\u003c\/strong\u003e. In other words, the risks of treating these cancers often outweigh the benefits.\u003c\/p\u003e\n\n\u003cp\u003eEarlier PSA screening trials produced mixed results, partly because of how they were designed. The PLCO cancer screening trial in the United States failed to show any benefit from organised annual PSA testing. But the control group was heavily contaminated. Men in the control group averaged 2.7 PSA tests versus 5 in the screening group, and many had testing outside the trial.\u003c\/p\u003e\n\n\u003cp\u003eThe ERSPC trial (European Randomised Study of Screening for Prostate Cancer) showed a \u003cstrong\u003e20% reduction in prostate cancer deaths\u003c\/strong\u003e after a 16-year follow-up — equating to \u003cstrong\u003e18 diagnoses needed to prevent one death\u003c\/strong\u003e. However, it also came with a large number of unnecessary biopsies: only \u003cstrong\u003e24% of biopsies\u003c\/strong\u003e led to a prostate cancer diagnosis. A large UK study, the CAP trial, found that a one-off PSA screening raised the number of diagnoses compared with the control group (\u003cstrong\u003e4.3% versus 3.6%\u003c\/strong\u003e), yet produced no statistically significant difference in prostate cancer death rates (rate ratio \u003cstrong\u003e0.96\u003c\/strong\u003e, 95% confidence interval 0.85 to 1.08) after a median follow-up of 10 years.\u003c\/p\u003e\n\n\u003cp\u003eBecause the benefits do not clearly outweigh the harms, the US Preventive Services Task Force (USPSTF) advises against population-wide screening. Instead it recommends a shared decision-making process for men aged \u003cstrong\u003e55 to 69\u003c\/strong\u003e, in which the patient and clinician weigh the risks and benefits together.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow This Review Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThis is a narrative review, not a new clinical trial. The authors identified and evaluated key published articles on emerging adjuncts and alternatives to PSA for early prostate cancer detection. They examined two broad categories of tools: new imaging strategies and molecular biomarker tests, including blood-based, urine-based and saliva-based tests.\u003c\/p\u003e\n\n\u003cp\u003eTheir goal was to assess whether these tools could deliver something PSA cannot. That is a cost-effective test with high sensitivity (the ability to correctly identify men who do have cancer) and high specificity (the ability to correctly identify men who do not). The goal was also to minimise the overdiagnosis of harmless tumours.\u003c\/p\u003e\n\n\u003ch2 id=\"psa-problem\"\u003eThe Problem With PSA Testing\u003c\/h2\u003e\n\n\u003cp\u003ePSA (encoded by a gene called KLK3) is a serine protease glycoprotein — a protein enzyme that liquefies the seminal coagulum, the gel-like substance in semen. It is a useful organ marker, but it cannot tell the difference between a harmless enlarged prostate and a dangerous tumour.\u003c\/p\u003e\n\n\u003cp\u003eThis single limitation drives most of the controversy around prostate cancer screening. Overdiagnosis — finding cancers that would never have caused symptoms — leads directly to overtreatment, which can bring side effects such as incontinence and erectile dysfunction. The search for better tools is therefore driven by one goal: find the dangerous cancers, and leave the harmless ones alone.\u003c\/p\u003e\n\n\u003ch2 id=\"mri\"\u003eMRI Imaging: The Current Gold Standard\u003c\/h2\u003e\n\n\u003cp\u003eMultiparametric MRI (mpMRI) of the prostate is currently the gold standard for identifying clinically significant prostate cancer (csPCa, cancer that is likely to grow and spread and needs treatment). MRI combines several imaging sequences: anatomical images (T1- and T2-weighted) plus functional sequences. The functional sequences include dynamic contrast-enhanced imaging (DCE, where a dye is injected to show blood flow). They also include diffusion-weighted imaging (DWI, which measures how freely water molecules move through tissue).\u003c\/p\u003e\n\n\u003cp\u003eCurrent European Association of Urology (EAU) guidelines strongly recommend mpMRI before biopsy, using the Prostate Imaging Reporting and Data System (PI-RADS) scoring system to grade suspicious areas from 1 to 5. In the UK, the National Institute for Health and Care Excellence (NICE) recommends a similar system called Likert scoring.\u003c\/p\u003e\n\n\u003cp\u003eThree landmark trials cemented the role of mpMRI before biopsy:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePROMIS\u003c\/strong\u003e showed that mpMRI before biopsy could reduce the need for biopsy in \u003cstrong\u003e27% of patients\u003c\/strong\u003e compared with PSA alone, and reduced the diagnosis of clinically insignificant prostate cancer.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePRECISION\u003c\/strong\u003e demonstrated that mpMRI-guided biopsy was non-inferior to standard transrectal ultrasound (TRUS)-guided biopsy, producing a \u003cstrong\u003e12% increase\u003c\/strong\u003e in csPCa detection (p=0.005) while reducing the number of biopsies by \u003cstrong\u003e28%\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMRI-FIRST\u003c\/strong\u003e showed that combining systematic and targeted biopsies detected more clinically significant cancers than either technique alone.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePut simply, MRI improves the accuracy of biopsies and helps many men avoid an unnecessary procedure.\u003c\/p\u003e\n\n\u003ch2 id=\"bpmri\"\u003eBiparametric MRI: A Faster, Contrast-Free Alternative\u003c\/h2\u003e\n\n\u003cp\u003eBiparametric MRI (bpMRI) removes the need for gadolinium contrast dye. This eliminates the dynamic contrast-enhanced (DCE) sequence, saving both time and money. Because no intravenous line or contrast agent is needed, bpMRI is simpler to perform and easier to scale for screening programmes.\u003c\/p\u003e\n\n\u003cp\u003eThe PRIME trial — a large, multi-centre study of \u003cstrong\u003e490 men\u003c\/strong\u003e — compared bpMRI with mpMRI for detecting clinically significant prostate cancer, and results were presented at the EAU 2024 meeting. The proportion of patients who needed a biopsy was similar: \u003cstrong\u003e273 out of 490 (56%) for bpMRI\u003c\/strong\u003e versus \u003cstrong\u003e279 out of 490 (57%) for mpMRI\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eDetection rates were also nearly identical. bpMRI was non-inferior to mpMRI for finding clinically significant disease (Gleason ≥3+4), with only a \u003cstrong\u003e0.4% lower detection rate\u003c\/strong\u003e: \u003cstrong\u003e143 out of 490 (29.2%) for mpMRI\u003c\/strong\u003e versus \u003cstrong\u003e141 out of 490 (28.8%) for bpMRI\u003c\/strong\u003e (p=0.5). Sensitivity was \u003cstrong\u003e99.3%\u003c\/strong\u003e for mpMRI and \u003cstrong\u003e97.9%\u003c\/strong\u003e for bpMRI. Specificity was \u003cstrong\u003e59.9%\u003c\/strong\u003e for mpMRI and \u003cstrong\u003e61.1%\u003c\/strong\u003e for bpMRI. In plain terms, the two methods performed essentially the same.\u003c\/p\u003e\n\n\u003cp\u003eOne important detail concerns image quality. PRIME only included high-quality MRIs, meaning only centres with an MRI quality score of 4 or 5 on the Prostate Imaging Quality (PI-QUAL) scale were selected. In Phase I, only \u003cstrong\u003e23 out of 71 scanners (32.4%)\u003c\/strong\u003e initially achieved a PI-QUAL score of 5. After targeted improvements to MRI protocols — adjusting image resolution, contrast timing and sequence parameters — \u003cstrong\u003e62 out of 64 scanners (96.9%)\u003c\/strong\u003e achieved a score of 5 in Phase II. This shows that systematic evaluation and protocol optimisation can substantially enhance MRI quality.\u003c\/p\u003e\n\n\u003cp\u003eThe IP7-PACIFIC trial is currently underway as a definitive study of the clinical utility and health economics of bpMRI versus mpMRI, and of visual registration versus image-guided fusion biopsy.\u003c\/p\u003e\n\n\u003ch2 id=\"ultrashort\"\u003eUltra-Short MRI Protocols\u003c\/h2\u003e\n\n\u003cp\u003eFor population-wide screening, the cost of MRI becomes a real limitation. Shorter protocols would improve access and reduce costs. A Dutch study compared three approaches: standard mpMRI, triplanar noncontrast MRI (standard bpMRI), and a fast monoplanar noncontrast MRI (fast bpMRI).\u003c\/p\u003e\n\n\u003cp\u003eAll three protocols achieved \u003cstrong\u003e95% sensitivity\u003c\/strong\u003e for detecting high-grade prostate cancer. The fast bpMRI slightly reduced specificity (\u003cstrong\u003e65% versus 69%\u003c\/strong\u003e) and led to a marginal increase in unnecessary biopsies and low-grade cancer detection. Scan times differed significantly:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003empMRI\u003c\/strong\u003e: 16 minutes\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ebpMRI\u003c\/strong\u003e: 13 minutes\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFast bpMRI\u003c\/strong\u003e: 8 minutes\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe trade-off is clear: faster scans mean slight reductions in accuracy but potentially much wider access.\u003c\/p\u003e\n\n\u003ch2 id=\"mri-screening\"\u003eMRI for Population-Wide Screening\u003c\/h2\u003e\n\n\u003cp\u003eCurrent EAU guidelines advise against using MRI for prostate cancer screening. Yet emerging evidence suggests MRI-based imaging could be an alternative to PSA-based screening. The EAU is collaborating with the European Union on the PRAISE-U project. This project aims to reduce prostate cancer illness and death by developing better screening strategies, including combining PSA and MRI.\u003c\/p\u003e\n\n\u003cp\u003eThe Göteborg2 study, involving \u003cstrong\u003e17,980 men\u003c\/strong\u003e, showed that MRI screening could reduce overdiagnosis of insignificant prostate cancer by half. Men with raised PSA (≥3 ng\/mL) were divided into two groups. The reference group underwent systematic and targeted biopsies; the experimental group underwent MRI-targeted biopsies only.\u003c\/p\u003e\n\n\u003cp\u003eIn the experimental group, the risk of overdiagnosing clinically insignificant prostate cancer was halved compared with the reference group (\u003cstrong\u003e0.6% versus 1.2%; relative risk 0.46; 95% CI 0.33 to 0.64; P\u0026lt;0.001\u003c\/strong\u003e). But this came at the cost of missing some clinically significant cancers (\u003cstrong\u003e0.9% versus 1.1%; relative risk 0.81; 95% CI 0.60 to 1.1\u003c\/strong\u003e). Reassuringly, in the reference group, all 10 clinically significant cancers detected by systematic biopsy alone were classified as intermediate risk and managed with active surveillance (close monitoring rather than immediate treatment).\u003c\/p\u003e\n\n\u003cp\u003eOne limitation: the negative predictive value (how reliably a negative scan rules out cancer) was not evaluated in the experimental group. Men with PI-RADS 1–2 findings did not receive a biopsy, and there was no extended follow-up for these men.\u003c\/p\u003e\n\n\u003cp\u003eA large systematic review and meta-analysis covering more than \u003cstrong\u003e80,000 men across 12 studies\u003c\/strong\u003e found that integrating MRI into prostate cancer screening pathways reduces unnecessary biopsies and overdiagnosis of insignificant disease, while maintaining detection rates of clinically significant cancer compared with PSA-only screening.\u003c\/p\u003e\n\n\u003cp\u003eSeveral other trials have tested MRI screening directly:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMVP trial (Canada)\u003c\/strong\u003e: bpMRI-only screening was compared with PSA. bpMRI had a cancer detection rate of \u003cstrong\u003e63% (15 out of 24)\u003c\/strong\u003e versus \u003cstrong\u003e29% (8 out of 23)\u003c\/strong\u003e for PSA alone (p=0.019). bpMRI also detected more clinically significant cancers (\u003cstrong\u003e73% versus 50%\u003c\/strong\u003e), with a relative risk of \u003cstrong\u003e2.77 (95% CI 0.89 to 8.59, p=0.07)\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eReIMAGINE trial\u003c\/strong\u003e: using bpMRI (T2-weighted plus diffusion-weighted sequences) for screening, \u003cstrong\u003e303 men\u003c\/strong\u003e underwent MRI. Of these, \u003cstrong\u003e48 men (16%)\u003c\/strong\u003e had a positive MRI, and of those, \u003cstrong\u003e25 (52%)\u003c\/strong\u003e had clinically significant cancer. Only \u003cstrong\u003e2 (4%)\u003c\/strong\u003e had clinically insignificant cancer. Notably, two thirds of men with a positive MRI and \u003cstrong\u003e60% of men who had clinically significant cancer\u003c\/strong\u003e had a PSA under 3 ng\/mL — meaning PSA alone would have missed them.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIP-1 PROSTAGRAM study (N=408)\u003c\/strong\u003e: compared PSA, bpMRI, and ultrasound (b-mode plus shear wave elastography). Abnormal results were found in \u003cstrong\u003e40 patients (9.9%; 95% CI 7.3%–13.2%)\u003c\/strong\u003e for PSA, \u003cstrong\u003e43 (10.6%; 95% CI 7.9%–14.0%)\u003c\/strong\u003e for bpMRI, and \u003cstrong\u003e52 (12.8%; 95% CI 9.9%–16.5%)\u003c\/strong\u003e for ultrasound. Using these cutoffs, bpMRI detected the most clinically significant cancers (\u003cstrong\u003e11\u003c\/strong\u003e), followed by PSA (\u003cstrong\u003e7\u003c\/strong\u003e) and ultrasound (\u003cstrong\u003e4\u003c\/strong\u003e).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVISIONING trial (Switzerland)\u003c\/strong\u003e: investigated bpMRI as primary opportunistic screening without using a PSA cutoff. Among \u003cstrong\u003e229 participants\u003c\/strong\u003e, \u003cstrong\u003e21\u003c\/strong\u003e were found to have clinically significant cancer — a detection rate of about \u003cstrong\u003e1 in every 11 bpMRI scans\u003c\/strong\u003e. The median PSA value in the cohort was only \u003cstrong\u003e1.26 ng\/mL\u003c\/strong\u003e. A protocol adjustment deferring biopsies for PI-RADS 3 lesions unless they showed persistence or upgrading reduced unnecessary biopsies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMRI-based screening has real limitations, including interobserver variability (different radiologists reading scans differently) and cost. A UK-based study is testing luminal index MRI (LI-MRI) for community screening, which offers shorter scan times of \u003cstrong\u003e5 minutes\u003c\/strong\u003e and lower costs.\u003c\/p\u003e\n\n\u003cp\u003eThe PRAISE-U project also conducted a systematic review of the cost-effectiveness of prostate cancer screening in Europe. Screening studies involving initially healthy populations found a median incremental cost-effectiveness ratio (ICER — the extra cost per unit of health gained) of \u003cstrong\u003e€56,487 per quality-adjusted life year (QALY)\u003c\/strong\u003e, ranging from \u003cstrong\u003e€5,872 to €372,948 per QALY\u003c\/strong\u003e. Risk-based screening strategies incorporating MRI were more cost-effective than no screening.\u003c\/p\u003e\n\n\u003cp\u003eMRI may also not be the best tool for younger men. The PROBASE trial evaluated risk-adapted screening based on baseline PSA rather than imaging alone. The PROBASE trial highlighted the limits of mpMRI for detecting cancer in younger men. Interpreting MRIs in younger patients is more complex because of normal age-related tissue changes.\u003c\/p\u003e\n\n\u003ch2 id=\"ultrasound\"\u003eUltrasound-Based Approaches\u003c\/h2\u003e\n\n\u003cp\u003eMultiparametric ultrasound (mpUS) combines contrast-enhanced ultrasound (CEUS), micro-Doppler, and real-time elastography. Currently there is no universally accepted standardised scoring system for mpUS in prostate cancer detection — a key barrier to wide adoption. The CAMDUS study (Cancer Diagnosis by Multiparametric Ultrasound of the Prostate) is one effort to address this.\u003c\/p\u003e\n\n\u003cp\u003eHigh-resolution micro-ultrasound is being tested in several major randomised trials, including:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMUSIC-Screen\u003c\/strong\u003e: a Phase 3, multicentre, international, non-inferiority randomised trial comparing prostate cancer screening using high-resolution micro-ultrasound versus mpMRI.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOPTIMUM\u003c\/strong\u003e: a 3-arm randomised controlled trial evaluating the role of 29 MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eA systematic review found that micro-ultrasound reduced detection of clinically insignificant cancers to \u003cstrong\u003e62 cases\u003c\/strong\u003e compared with \u003cstrong\u003e115 cases\u003c\/strong\u003e for systematic biopsies (detection ratio \u003cstrong\u003e0.55\u003c\/strong\u003e, 95% CI 0.41–0.73, with very low inconsistency between studies, I² = 0%). These findings were corroborated in the first multicentre prospective trial comparing micro-US and mpMRI targeted biopsies: micro-US-guided biopsies were non-inferior for detecting clinically significant cancer.\u003c\/p\u003e\n\n\u003ch2 id=\"blood-tests\"\u003eBlood-Based Biomarker Tests\u003c\/h2\u003e\n\n\u003cp\u003eBlood-based biomarker tests can improve risk stratification — reducing unnecessary biopsies while maintaining detection of clinically significant cancers compared with PSA alone. The review highlights three that have been studied most extensively:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStockholm3 (STHLM3)\u003c\/strong\u003e: combines \u003cstrong\u003efive protein markers\u003c\/strong\u003e (human glandular kallikrein 2, microseminoprotein beta, microphage inhibitory cytokine-1, total PSA and free PSA) with \u003cstrong\u003e101 single nucleotide polymorphisms (SNPs, small genetic variations)\u003c\/strong\u003e, plus clinical data on age, family history and previous prostate biopsy. It is intended for men aged \u003cstrong\u003e45 to 74\u003c\/strong\u003e with no previous prostate cancer diagnosis and a PSA of \u003cstrong\u003e≥1.5\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e4Kscore\u003c\/strong\u003e: measures \u003cstrong\u003efour prostate-specific kallikreins\u003c\/strong\u003e (total PSA, free PSA, intact PSA, and human kallikrein 2), combined with age, digital rectal exam (DRE) findings, and prior biopsy history. It is intended for men aged \u003cstrong\u003e45 and older\u003c\/strong\u003e with an abnormal PSA or DRE before a first biopsy, or after a negative biopsy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProstate Health Index (PHI)\u003c\/strong\u003e: uses \u003cstrong\u003ethree kallikrein assays\u003c\/strong\u003e (PSA, free PSA and [-2]proPSA). It is intended for men aged \u003cstrong\u003e50 and older\u003c\/strong\u003e with a PSA between \u003cstrong\u003e2 and 10\u003c\/strong\u003e and a negative DRE.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"urine-tests\"\u003eUrine-Based Biomarker Tests\u003c\/h2\u003e\n\n\u003cp\u003eUrine-based biomarker tests have been examined for early detection and risk stratification of clinically significant disease as adjuncts to PSA testing. Three are highlighted:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExoDx\u003c\/strong\u003e: measures exosomal RNA expression of three genes — \u003cem\u003eERG\u003c\/em\u003e, \u003cem\u003ePCA3\u003c\/em\u003e and \u003cem\u003eSPDEF\u003c\/em\u003e. It is intended for men aged \u003cstrong\u003e50 and older\u003c\/strong\u003e with a PSA between \u003cstrong\u003e2 and 10\u003c\/strong\u003e, for either a first or repeat biopsy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMy Prostate Score (MPS)\u003c\/strong\u003e: combines urinary PCA3 and TMPRSS2:ERG (measured after a digital rectal exam) with serum PSA. It estimates the risk of a Gleason Grade ≥2 tumour on biopsy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSelectMDx\u003c\/strong\u003e: measures mRNA expression of \u003cem\u003eDLX1\u003c\/em\u003e (Distal-Less Homeobox 1) and \u003cem\u003eHOXC6\u003c\/em\u003e (Homeobox protein Hox-C6), after a digital rectal exam, alongside age, DRE findings, PSA and prostate volume. It estimates the risk of any prostate cancer and of Gleason score ≥7 on biopsy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"prs\"\u003eSaliva-Based Genetic Risk Scores\u003c\/h2\u003e\n\n\u003cp\u003eSaliva-derived polygenic risk scores (PRS) combine the effects of many common genetic variants into a single risk number. Saliva-derived polygenic risk scores hold potential as a non-invasive screening tool to identify at-risk patient groups. Alongside biomarker tests such as the Stockholm3, PRS are being studied in trials including \u003cstrong\u003eBARCODE1\u003c\/strong\u003e (Biomarker for Risk of Prostate Cancer: 1st Study) and \u003cstrong\u003ePROFILE\u003c\/strong\u003e (Germline Genetic Profiling: Correlation with Targeted Prostate Cancer Screening and Treatment).\u003c\/p\u003e\n\n\u003cp\u003eThe logic is straightforward: rather than screening every man with the same test, use genetic and molecular risk scores to focus imaging-based early detection on men at highest risk.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe review makes several points that matter directly to men considering prostate cancer screening.\u003c\/p\u003e\n\n\u003cp\u003eFirst, PSA testing as currently performed finds a lot of cancers that do not need treatment. Only about one in three men with an elevated PSA actually has cancer. In many of the men diagnosed, the tumours are low risk. These tumours have less than a 3% chance of causing death over 10 to 15 years even without treatment.\u003c\/p\u003e\n\n\u003cp\u003eSecond, MRI has already transformed diagnosis by reducing unnecessary biopsies and detecting more clinically significant cancers. In the PRECISION trial, adding MRI to the biopsy pathway increased detection of clinically significant cancer by 12% and reduced biopsies by 28%.\u003c\/p\u003e\n\n\u003cp\u003eThird, newer imaging options — bpMRI and potentially micro-ultrasound — appear to offer similar accuracy to standard mpMRI at lower cost. The PRIME trial showed essentially identical detection rates between bpMRI and mpMRI (29.2% versus 28.8%), and the fast bpMRI protocol takes only 8 minutes versus 16 minutes for the standard version.\u003c\/p\u003e\n\n\u003cp\u003eFourth, MRI screening can detect cancers that PSA misses. In the ReIMAGINE trial, 60% of men who had clinically significant cancer had a PSA below 3 ng\/mL — meaning PSA alone would have missed them entirely.\u003c\/p\u003e\n\n\u003cp\u003eFifth, molecular biomarkers and genetic risk scores could help target who needs imaging in the first place, potentially making screening programmes more cost-effective. The PRAISE-U review found MRI-based risk-stratified screening more cost-effective than no screening.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of the Evidence\u003c\/h2\u003e\n\n\u003cp\u003eThe review is careful to note where the evidence falls short. These are important caveats for anyone reading headlines about new screening tools.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo long-term outcome data yet.\u003c\/strong\u003e Most studies of MRI-based screening measure cancer detection, not whether fewer men die. Only longer follow-up will tell us whether these tools save lives.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRandomised trials are still needed.\u003c\/strong\u003e The authors state clearly that prospective randomised clinical trials are urgently needed to evaluate how different modalities perform in population-wide screening. Currently most comparisons rely on non-randomised or single-centre data.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMRI has inherent limitations.\u003c\/strong\u003e Interobserver variability (different radiologists disagreeing) and cost remain barriers to widespread screening use.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNegative predictive value is not fully established.\u003c\/strong\u003e In the Göteborg2 study, the researchers could not evaluate how reliably a negative MRI rules out cancer. Men with PI-RADS 1–2 findings did not receive biopsies and lacked extended follow-up.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAge matters.\u003c\/strong\u003e The PROBASE trial showed that MRI may not perform as well in younger men, because normal age-related changes make images harder to interpret.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMRI-quality variability.\u003c\/strong\u003e In the PRIME trial, only 32.4% of scanners initially achieved the highest quality score. Results may not be reproducible at centres without rigorous quality control.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo standardised scoring for ultrasound.\u003c\/strong\u003e There is currently no universally accepted scoring system for mpUS, limiting its comparability across studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003ePractical Recommendations\u003c\/h2\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss PSA screening with your clinician.\u003c\/strong\u003e The USPSTF recommends a shared decision-making conversation for men aged 55 to 69 — weighing risks and benefits together. There is no single right answer for everyone.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow what a raised PSA means — and doesn't mean.\u003c\/strong\u003e Only about 1 in 3 men with an elevated PSA will turn out to have cancer at first assessment. Repeat testing, additional blood tests such as PHI, 4Kscore or Stockholm3, or an MRI can clarify the picture before biopsy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about MRI before biopsy.\u003c\/strong\u003e International guidelines strongly recommend MRI before prostate biopsy. It has been shown to detect more clinically significant cancers while reducing the number of unnecessary biopsies by about a quarter.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand your Gleason score.\u003c\/strong\u003e If you are diagnosed with Gleason ≤6 disease, low risk (PSA under 10 ng\/mL and stage ≤T2a), ask about active surveillance rather than immediate treatment. Over 10–15 years, the risk of dying from such cancer is less than 3% even without treatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about newer biomarker tests if your PSA is borderline.\u003c\/strong\u003e Tests such as 4Kscore, Stockholm3, PHI, SelectMDx, ExoDx or MyProstateScore may help refine your risk estimate and avoid an unnecessary biopsy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWatch for ongoing trial results.\u003c\/strong\u003e Major trials including MUSIC-Screen, OPTIMUM, IP7-PACIFIC and PRAISE-U will provide stronger evidence about which screening strategies work best. Ask your clinician whether participating in a trial is appropriate for you.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eLooking to the future, the authors note that new technologies — particularly artificial intelligence and diagnostic tests that incorporate circulating tumour markers — may further reshape how prostate cancer is detected early.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat does an elevated PSA result actually mean?\u003c\/h3\u003e\n\u003cp\u003ePSA is made by the prostate and can rise for reasons other than cancer, including an enlarged non-cancerous prostate or prostate inflammation. Only about one in three men with an elevated PSA will actually have cancer found on initial assessment. A raised result is therefore a prompt for further discussion, not a diagnosis, and repeat testing or additional tests can clarify the picture.\u003c\/p\u003e\n\u003ch3\u003eWhy is MRI recommended before a prostate biopsy?\u003c\/h3\u003e\n\u003cp\u003eInternational guidelines strongly recommend MRI before biopsy. In the PRECISION trial, adding MRI to the biopsy pathway increased detection of clinically significant cancer by 12% and reduced the number of biopsies by 28%. The PROMIS trial found MRI before biopsy could reduce the need for biopsy in 27% of patients compared with PSA alone, while reducing diagnosis of insignificant cancers.\u003c\/p\u003e\n\u003ch3\u003eWhat is biparametric MRI, and how does it compare with standard MRI?\u003c\/h3\u003e\n\u003cp\u003eBiparametric MRI removes the need for gadolinium contrast dye, so no intravenous line is required, saving time and money. In the PRIME trial of 490 men, detection of clinically significant cancer was nearly identical: 29.2% for standard multiparametric MRI versus 28.8% for biparametric MRI. The proportion needing biopsy was also similar, 57% versus 56%.\u003c\/p\u003e\n\u003ch3\u003eIf I am diagnosed with Gleason 6 prostate cancer, do I need treatment straight away?\u003c\/h3\u003e\n\u003cp\u003eFor men with Gleason 6 tumours classified as low risk, the risk of dying from prostate cancer over 10 to 15 years is less than 3%. Low risk means PSA under 10 ng\/mL and stage T2a or lower. This is true even without any treatment. The article suggests asking about active surveillance, which means close monitoring rather than immediate treatment, because the risks of treating these cancers often outweigh the benefits.\u003c\/p\u003e\n\u003ch3\u003eCan MRI screening find cancers that a PSA test would miss?\u003c\/h3\u003e\n\u003cp\u003eIn the ReIMAGINE trial, 303 men had biparametric MRI screening. Of the men found to have clinically significant cancer, 60% had a PSA below 3 ng\/mL, meaning PSA alone would have missed them. This suggests MRI-based screening can detect some cancers that PSA testing does not flag, though longer follow-up is needed to show whether this saves lives.\u003c\/p\u003e\n\u003ch3\u003eWhat are the main limitations of using MRI for prostate cancer screening?\u003c\/h3\u003e\n\u003cp\u003eMRI has real limitations. Different radiologists can read scans differently, and cost remains a barrier. In the PRIME trial, only 32.4% of scanners initially reached the highest quality score, so results may not be reproducible without rigorous quality control. Also, in the Göteborg2 study, how reliably a negative MRI rules out cancer could not be fully evaluated.\u003c\/p\u003e\n\u003ch3\u003eAre there blood or urine tests that can help avoid an unnecessary biopsy?\u003c\/h3\u003e\n\u003cp\u003eSeveral blood tests are intended to refine risk estimates in men with borderline PSA results. These include Stockholm3, 4Kscore and the Prostate Health Index. Urine tests such as ExoDx, My Prostate Score and SelectMDx are also intended to refine risk estimates in men with borderline PSA results. They may help reduce unnecessary biopsies while maintaining detection of clinically significant cancers compared with PSA alone. Ask your clinician whether any are appropriate for you.\u003c\/p\u003e\n\u003ch3\u003eIf my PSA is elevated but my biopsy is recommended, when should I get a second opinion before going ahead?\u003c\/h3\u003e\n\u003cp\u003eAn elevated PSA does not mean cancer: only about one in three men with a raised PSA have cancer found at first assessment. Before proceeding to biopsy, a second opinion can review whether repeat testing, additional blood tests such as PHI, 4Kscore or Stockholm3, or an MRI should come first. Guidelines strongly recommend MRI before biopsy, since it detects more clinically significant cancers while reducing unnecessary biopsies by roughly a quarter. A review of your PSA history, prior imaging and pathology can clarify whether biopsy is truly needed. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Emerging tools for the early detection of prostate cancer\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Muhammad Haider, Jeffrey J. Leow, Tobias Nordström, Ashkan Mortezavi, Peter Albers, Rakesh Heer, and Prabhakar Rajan\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthor affiliations:\u003c\/strong\u003e Barts Cancer Institute, Queen Mary University of London, UK; Barts Health NHS Trust, London, UK; University College London Hospitals NHS Foundation Trust, London, UK; Tan Tock Seng Hospital, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Danderyds Sjukhus and Karolinska Institutet, Stockholm, Sweden; University Hospital Zürich, Switzerland; University Hospital Düsseldorf and German Cancer Research Center, Heidelberg, Germany; Imperial College and Imperial College Healthcare NHS Trust, London, UK\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication details:\u003c\/strong\u003e BJUI Compass, 2025; 6: e70081. Published by John Wiley \u0026amp; Sons Ltd on behalf of BJU International Company. Open access under a Creative Commons Attribution License. DOI: 10.1002\/bco2.70081. Received 9 April 2025; Accepted 23 August 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and should not replace personalised medical advice. Please consult your clinician about your individual screening options.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47576610242716,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/pt\/products\/new-tools-for-detecting-prostate-cancer-early-a-patients-guide-to-emerging-screening-technologies","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}